Global X China Semiconductor ETF(03191.HK) rose 6.21% to HKD 84.540
Newtimespace News, as of 11:12 on May 11, Global X China Semiconductor ETF(03191.HK) was quoted at HKD 84.540, up 6.21%. The ETF opened at HKD 81.000, with a high of HKD 84.620 and a low of HKD 81.000. The latest NAV per unit is HKD 81.082, with a premium rate of 0.59%. The asset size is approximately HKD 2.206 billion.
Global X China Semiconductor ETF(03191.HK) tracks the performance of the FactSet China Semiconductor Index. As a thematic ETF focused on China's semiconductor industry, it primarily invests in companies engaged in semiconductor production and related businesses in China, covering areas such as integrated circuit design, wafer foundry, packaging and testing, and semiconductor production equipment. Its holdings are highly concentrated in leading domestic semiconductor and hard-tech companies.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment